Our goal is early-disease detection.

Breathe BioMedical™ is developing a powerful technology platform that is poised to screen for often deadly diseases using only breath.

Breathe BioMedical could make early disease screening of cancer and other diseases through breath analysis the new standard for routine screening.

Our technology works by identifying the biomarkers of disease. We have active studies underway where we are exploring the potential of using exhaled breath to detect disease. This technology could revolutionize multi-disease screening.

Our pursuit is to make our simple breath test available in physician offices, clinics and pharmacies. In a single test we could screen for numerous diseases.

Our Mission: To empower people with a simple breath test that provides early detection of cancer and other diseases.

Our Vision: A non-invasive screening test to save lives.

Just breathe®


Our most recent research demonstrated early-stage breast cancer detection in the breath with 88.2% accuracy, while also identifying that the results were independent of breast tissue density. This groundbreaking research was conducted by Dr. Farah Naz, using Breathe BioMedical’s technology, and was published as an online abstract at the ASCO 2023 Annual Meeting.
View 2023 ASCO Breast Cancer AbstractView 2022 ASCO Breast Cancer AbstractView Journal of Breath Research PaperView ASCO AbstractView Breath Biopsy PosterView COVID-19 Pneumonia Abstract


Breathe BioMedical has an amazing team of partners who conduct research with our technology and support our goals.

ISO 13485 Certified

ISO 13485 Certified is an international standard for quality systems for medical device manufacturers across the globe. This certification demonstrates, by third party review, that Breathe BioMedical’s full end-to-end quality management system meets the highest standard for safety and quality.